CEO SUMMARY: It’s a case of the little fish gobbling the big fish, as Opko Health—with revenue of $91 million—will be acquiring Bio-Reference Laboratories, with revenue of $832 million. But the more interesting aspect of the story is that the CEO of Opko Health is a physician worth $5 billion and highly respected by Wall Street. It could be that Bio-Reference CEO Marc Grodman, M.D., has gained a shrewd advisor and powerful ally in Phillip Frost, M.D., the Chair and CEO of Opko Health.
Opko Pays $1.47 Billion to Buy Bio-Reference Lab
Nation’s third largest lab company to become business unit of a pharma and diagnostics firm
- By Robert Michel
- > From the Volume XXII NO. 9 - June 22, 2015 Issue
- Tags: biopsies, cap, clinical lab, clinical lab test, clinical lab testing, Clinical Laboratory, clinical laboratory manager, clinical laboratory test, clinical laboratory testing, clinical laboratory testing market, companion diagnostic, Companion diagnostics, dark report, Diagnostic technology, ehi, Esoteric testing, genetic sequencing, genetic test, genetic testing, genomics, lab industry, lab test, lab testing, lab testing services, laboratories, laboratory companies, laboratory manager, laboratory managers, laboratory medicine, laboratory test, laboratory testing, molecular diagnostic, pathologists, reference laboratories, the clinical laboratory, the dark report
